## CRL: Charles River Laboratories Inte - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 2.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($171.41)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Arrowstreet Capital Limited Partnership Purchases 225,027 Shares of Charles River Laboratories International, Inc. $CRL**
- Source: MarketBeat | 20251204T080937 | Bullish | Relevance: 99%
- Arrowstreet Capital Limited Partnership significantly increased its stake in Charles River Laboratories International, Inc. (NYSE: CRL) by 63.6% in the second quarter, acquiring an additional 225,027 shares, bringing its total holdings to 578,609 shares valued at approximately $87.79 million. Other institutional investors like Wellington Management, Allspring Global Investments, and Kayne Anderson Rudnick also increased their positions, leading to a high institutional ownership of 98.91% for CRL. Analysts currently rate the stock as a "Moderate Buy" with a consensus target price of $190.86, following the company's recent earnings beat.

**2. JPMorgan Chase & Co. Sells 481,286 Shares of Charles River Laboratories International, Inc. $CRL**
- Source: MarketBeat | 20251204T101446 | Somewhat-Bullish | Relevance: 98%
- JPMorgan Chase & Co. significantly reduced its stake in Charles River Laboratories International (NYSE:CRL) during the second quarter, selling 481,286 shares and retaining 277,106 shares valued at approximately $42.05 million. Analyst sentiment for Charles River remains largely positive, with a "Moderate Buy" consensus and an average price target of $190.86. The company recently reported strong quarterly earnings, beating EPS and revenue estimates.

**3. What Charles River Laboratories International (CRL)'s Improving Discovery and Safety Assessment Bookings Trend Means For Shareholders**
- Source: Simply Wall Street | 20251205T110847 | Somewhat-Bullish | Relevance: 98%
- Charles River Laboratories International (CRL) recently highlighted improving Discovery and Safety Assessment net book-to-bill ratios at a healthcare conference, suggesting a recovery in underlying demand. While this trend indicates improving order momentum, the company still faces risks such as cancellations and pressure on margins. Investors should consider these factors despite the projected long-term revenue and earnings growth.

**4. Charles River Laboratories (CRL) Shares Skyrocket, What You Need To Know**
- Source: Markets Financial Content | 20251203T215500 | Bullish | Relevance: 98%
- Shares of Charles River Laboratories (CRL) jumped 6.1% after the company provided an encouraging business update at an investor conference, highlighting positive demand trends in its Discovery and Safety Assessment (DSA) segment. The company reported that its net book-to-bill ratio has risen each month since the start of the third fiscal quarter, leading to optimism about upward trends despite potential short-term holiday seasonality. CRL shares closed at $184.69, reflecting a 5.7% increase, and are trading near their 52-week high.

**5. Charles River Laboratories Updates on DSA Trends at Conference**
- Source: TradingView | 20251203T130614 | Bullish | Relevance: 98%
- Charles River Laboratories presented at the Evercore Healthcare Conference on December 3, 2025, to discuss demand trends for DSA. The company highlighted improvements in DSA net book-to-bill monthly since Q3 2025, noting positive momentum since mid-2025, though holiday seasonality might impact short-term bookings. This information was originally filed with the SEC.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Morgan Stanley | $185 | $170 | +9% |
| 2025-11-10 | TD Cowen | $197 | $205 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Morgan Stanley | main | Equal-Weight |
| 2025-11-10 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.5%)
- Blackrock Inc.: 7.8% (+5.5%)
- Wellington Managemen: 6.5% (-15.3%)
- Allspring Global Inv: 4.4% (-4.9%)
- State Street Corpora: 3.7% (-1.5%)

### Key Risks

1. Market regime shift could impact high-beta names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.13 indicates undervaluation relative to growth. Forward P/E 16.8x stretched relative to 7% growth. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.2B |
| Beta | 1.64 |
| 52W Range | $91.86 - $202.72 |
| Short Interest | 6.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.13 |
| Forward P/E | 16.8 |
| Current P/E | 18.0 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.6% over 5 days). Below STRENGTH zone by 0.9pp (needs >3.0% for momentum thesis). MRS_5 at 1.4% confirms short-term momentum alignment. Outperforming sector by 4.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.79), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.06% (CS: 72) | Neutral |
| RSI_14 | 62.5 | Neutral |
| MACD Histogram | 1.79 | Bullish |
| vs SMA20 | 1.070x | Above |
| vs SMA50 | 1.058x | Above |
| vs SMA200 | 1.182x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $184.31
- **Stop Loss:** $171.41 (7.0% risk)
- **Target:** $197.21 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 38
- **Position Value:** $7,003.78
- **Portfolio %:** 7.00%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-18 (Est: $2.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.34 | $2.43 | +3.9% |
| 2025Q2 | $2.55 | $3.12 | +22.4% |
| 2025Q1 | $2.07 | $2.34 | +12.8% |
| 2024Q4 | $2.53 | $2.66 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*